Q-omics provides the consensus-scored HNRNPH1 profile across patient tissues and cancer cell-line models. HNRNPH1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HNRNPH1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, HNRNPH1 protein abundance shows 24,891 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where HNRNPH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPH1 survival associations across molecular data types. HNRNPH1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPH1 RNA expression–survival associations across cancer types. High HNRNPH1 expression shows unfavorable associations in ACC, LIHC, KICH and LGG, but favorable associations in READ and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HNRNPH1 RNA expression.
This table summarizes HNRNPH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HNRNPH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPH1 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, HNSC, KIRC and CHOL. The COAD box plot shows higher HNRNPH1 RNA expression in tumor versus normal tissue (log2 FC = +0.758, t-test p < 0.001).
This table shows molecular features associated with HNRNPH1 in patient tissues and cancer cell lines. In patient samples, HNRNPH1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HNRNPH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
